{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:18:06Z","timestamp":1793326686455,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI171200"],"award-info":[{"award-number":["R01 AI171200"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI171200"],"award-info":[{"award-number":["R01 AI171200"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32 AI049820"],"award-info":[{"award-number":["T32 AI049820"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI171200"],"award-info":[{"award-number":["R01 AI171200"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UC7AI180311"],"award-info":[{"award-number":["UC7AI180311"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UC7AI180311"],"award-info":[{"award-number":["UC7AI180311"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000861","name":"Burroughs Wellcome Fund","doi-asserted-by":"publisher","award":["CAMS 1013362"],"award-info":[{"award-number":["CAMS 1013362"]}],"id":[{"id":"10.13039\/100000861","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-025-01200-2","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T07:13:10Z","timestamp":1751440390000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Humoral immunity is sufficient to protect mice against Rift Valley fever encephalitis following percutaneous exposure"],"prefix":"10.1038","volume":"10","author":[{"given":"Karina","family":"Mueller Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique J.","family":"Barbeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingqing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian H.","family":"Bird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita K.","family":"McElroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"1200_CR1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.antiviral.2018.05.009","volume":"156","author":"CM McMillen","year":"2018","unstructured":"McMillen, C. M. & Hartman, A. L. Rift Valley fever in animals and humans: current perspectives. Antivir. Res 156, 29\u201337 (2018).","journal-title":"Antivir. Res"},{"key":"1200_CR2","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3390\/v3050493","volume":"3","author":"T Ikegami","year":"2011","unstructured":"Ikegami, T. & Makino, S. The pathogenesis of Rift Valley fever. Viruses 3, 493\u2013519 (2011).","journal-title":"Viruses"},{"key":"1200_CR3","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1086\/378747","volume":"37","author":"TA Madani","year":"2003","unstructured":"Madani, T. A. et al. Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics. Clin. Infect. Dis. 37, 1084\u20131092 (2003).","journal-title":"Clin. Infect. Dis."},{"key":"1200_CR4","doi-asserted-by":"publisher","first-page":"554","DOI":"10.3201\/eid1003.020817","volume":"10","author":"AA Alrajhi","year":"2004","unstructured":"Alrajhi, A. A., Al-Semari, A. & Al-Watban, J. Rift Valley fever encephalitis. Emerg. Infect. Dis. 10, 554\u2013555 (2004).","journal-title":"Emerg. Infect. Dis."},{"key":"1200_CR5","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.3389\/fmicb.2020.01962","volume":"11","author":"HN Cartwright","year":"2020","unstructured":"Cartwright, H. N., Barbeau, D. J. & McElroy, A. K. Rift Valley fever virus is lethal in different inbred mouse strains independent of sex. Front. Microbiol. 11, 1962 (2020).","journal-title":"Front. Microbiol."},{"key":"1200_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3389\/fcimb.2012.00105","volume":"2","author":"JM Bales","year":"2012","unstructured":"Bales, J. M., Powell, D. S., Bethel, L. M., Reed, D. S. & Hartman, A. L. Choice of inbred rat strain impacts lethality and disease course after respiratory infection with Rift Valley fever virus. Front. Cell Infect. Microbiol. 2, 105 (2012).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"1200_CR7","doi-asserted-by":"publisher","first-page":"e2874","DOI":"10.1371\/journal.pntd.0002874","volume":"8","author":"KA Dodd","year":"2014","unstructured":"Dodd, K. A. et al. Rift Valley fever virus encephalitis is associated with an ineffective systemic immune response and activated T cell infiltration into the CNS in an immunocompetent mouse model. PLoS Negl. Trop. Dis. 8, e2874 (2014).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"1200_CR8","doi-asserted-by":"crossref","unstructured":"Hickerson, B. T. et al. Pathogenesis of Rift Valley fever virus aerosol infection in STAT2 knockout hamsters. Viruses 10, 651 (2018).","DOI":"10.3390\/v10110651"},{"key":"1200_CR9","doi-asserted-by":"publisher","first-page":"e2156","DOI":"10.1371\/journal.pntd.0002156","volume":"7","author":"C Reed","year":"2013","unstructured":"Reed, C. et al. Aerosol exposure to Rift Valley fever virus causes earlier and more severe neuropathology in the murine model, which has important implications for therapeutic development. PLoS Negl. Trop. Dis. 7, e2156 (2013).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"1200_CR10","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1146\/annurev-virology-093022-011544","volume":"11","author":"LR Wilson","year":"2024","unstructured":"Wilson, L. R. & McElroy, A. K. Rift Valley fever virus encephalitis: viral and host determinants of pathogenesis. Annu Rev. Virol. 11, 309\u2013325 (2024).","journal-title":"Annu Rev. Virol."},{"key":"1200_CR11","doi-asserted-by":"publisher","first-page":"e1010649","DOI":"10.1371\/journal.ppat.1010649","volume":"18","author":"HN Cartwright","year":"2022","unstructured":"Cartwright, H. N. et al. Genetic diversity of collaborative cross mice enables identification of novel rift valley fever virus encephalitis model. PLoS Pathog. 18, e1010649 (2022).","journal-title":"PLoS Pathog."},{"key":"1200_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00769-w","volume":"8","author":"C Alkan","year":"2023","unstructured":"Alkan, C., Jurado-Cobena, E. & Ikegami, T. Advancements in Rift Valley fever vaccines: a historical overview and prospects for next generation candidates. NPJ Vaccines 8, 171 (2023).","journal-title":"NPJ Vaccines"},{"key":"1200_CR13","doi-asserted-by":"publisher","first-page":"9798","DOI":"10.1128\/JVI.78.18.9798-9806.2004","volume":"78","author":"A Billecocq","year":"2004","unstructured":"Billecocq, A. et al. NSs protein of Rift Valley fever virus blocks interferon production by inhibiting host gene transcription. J. Virol. 78, 9798\u20139806 (2004).","journal-title":"J. Virol."},{"key":"1200_CR14","doi-asserted-by":"publisher","first-page":"E75","DOI":"10.1111\/j.1749-6632.2009.05054.x","volume":"1171","author":"T Ikegami","year":"2009","unstructured":"Ikegami, T. et al. Dual functions of Rift Valley fever virus NSs protein: inhibition of host mRNA transcription and post-transcriptional downregulation of protein kinase PKR. Ann. N. Y. Acad. Sci. 1171, E75\u2013E85 (2009).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"1200_CR15","doi-asserted-by":"publisher","first-page":"e2670","DOI":"10.1371\/journal.pntd.0002670","volume":"8","author":"RC Kading","year":"2014","unstructured":"Kading, R. C. et al. Deletion of the NSm virulence gene of Rift Valley fever virus inhibits virus replication in and dissemination from the midgut of Aedes aegypti mosquitoes. PLoS Negl. Trop. Dis. 8, e2670 (2014).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"1200_CR16","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01506-21","volume":"95","author":"DJ Barbeau","year":"2021","unstructured":"Barbeau, D. J. et al. Identification and characterization of Rift Valley fever virus-specific T cells reveals a dependence on CD40\/CD40L interactions for prevention of encephalitis. J. Virol. 95, e0150621 (2021).","journal-title":"J. Virol."},{"key":"1200_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00551-4","volume":"7","author":"JD Doyle","year":"2022","unstructured":"Doyle, J. D., Barbeau, D. J., Cartwright, H. N. & McElroy, A. K. Immune correlates of protection following Rift Valley fever virus vaccination. NPJ Vaccines 7, 129 (2022).","journal-title":"NPJ Vaccines"},{"key":"1200_CR18","doi-asserted-by":"publisher","first-page":"6161","DOI":"10.1128\/JVI.00337-13","volume":"87","author":"KA Dodd","year":"2013","unstructured":"Dodd, K. A., McElroy, A. K., Jones, M. E., Nichol, S. T. & Spiropoulou, C. F. Rift Valley fever virus clearance and protection from neurologic disease are dependent on CD4+ T cell and virus-specific antibody responses. J. Virol. 87, 6161\u20136171 (2013).","journal-title":"J. Virol."},{"key":"1200_CR19","doi-asserted-by":"crossref","unstructured":"Harmon, J. R. et al. CD4 T cells, CD8 T cells, and monocytes coordinate to prevent Rift Valley fever virus encephalitis. J. Virol. 92, e01270-18 (2018).","DOI":"10.1128\/JVI.01270-18"},{"key":"1200_CR20","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2024.2373313","volume":"13","author":"CK Prajeeth","year":"2024","unstructured":"Prajeeth, C. K. et al. Immune correlates of protection of the four-segmented Rift Valley fever virus candidate vaccine in mice. Emerg. Microbes Infect. 13, 2373313 (2024).","journal-title":"Emerg. Microbes Infect."},{"key":"1200_CR21","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.4269\/ajtmh.22-0356","volume":"107","author":"DM Watts","year":"2022","unstructured":"Watts, D. M. et al. Estimation of the minimal Rift Valley fever virus protective neutralizing antibody titer in human volunteers immunized with MP-12 vaccine based on protection in a mouse model of disease. Am. J. Trop. Med. Hyg. 107, 1091\u20131098 (2022).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"1200_CR22","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.virol.2010.08.016","volume":"407","author":"DR Smith","year":"2010","unstructured":"Smith, D. R. et al. The pathogenesis of Rift Valley fever virus in the mouse model. Virology 407, 256\u2013267 (2010).","journal-title":"Virology"},{"key":"1200_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1081107","volume":"13","author":"SA Plotkin","year":"2022","unstructured":"Plotkin, S. A. Recent updates on correlates of vaccine-induced protection. Front. Immunol. 13, 1081107 (2022).","journal-title":"Front. Immunol."},{"key":"1200_CR24","doi-asserted-by":"publisher","first-page":"10883","DOI":"10.1128\/JVI.00961-14","volume":"88","author":"PJ Wichgers Schreur","year":"2014","unstructured":"Wichgers Schreur, P. J., Oreshkova, N., Moormann, R. J. & Kortekaas, J. Creation of Rift Valley fever viruses with four-segmented genomes reveals flexibility in bunyavirus genome packaging. J. Virol. 88, 10883\u201310893 (2014).","journal-title":"J. Virol."},{"key":"1200_CR25","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1186\/1743-422X-10-349","volume":"10","author":"GM Warimwe","year":"2013","unstructured":"Warimwe, G. M. et al. Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice. Virol. J. 10, 349 (2013).","journal-title":"Virol. J."},{"key":"1200_CR26","doi-asserted-by":"publisher","first-page":"14926","DOI":"10.1073\/pnas.1112149108","volume":"108","author":"JF Papin","year":"2011","unstructured":"Papin, J. F. et al. Recombinant Rift Valley fever vaccines induce protective levels of antibody in baboons and resistance to lethal challenge in mice. Proc. Natl. Acad. Sci. USA 108, 14926\u201314931 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1200_CR27","doi-asserted-by":"publisher","first-page":"e59210","DOI":"10.1371\/journal.pone.0059210","volume":"8","author":"W Xu","year":"2013","unstructured":"Xu, W. et al. The nucleocapsid protein of Rift Valley fever virus is a potent human CD8+ T cell antigen and elicits memory responses. PLoS One 8, e59210 (2013).","journal-title":"PLoS One"},{"key":"1200_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2020.101669","volume":"23","author":"D Wright","year":"2020","unstructured":"Wright, D. et al. Naturally acquired Rift Valley fever virus neutralizing antibodies predominantly target the Gn glycoprotein. iScience 23, 101669 (2020).","journal-title":"iScience"},{"key":"1200_CR29","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1743-422X-6-6","volume":"6","author":"N Lagerqvist","year":"2009","unstructured":"Lagerqvist, N. et al. Characterisation of immune responses and protective efficacy in mice after immunisation with Rift Valley fever virus cDNA constructs. Virol. J. 6, 6 (2009).","journal-title":"Virol. J."},{"key":"1200_CR30","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1016\/j.vaccine.2010.02.018","volume":"28","author":"G Lorenzo","year":"2010","unstructured":"Lorenzo, G., Martin-Folgar, R., Hevia, E., Boshra, H. & Brun, A. Protection against lethal Rift Valley fever virus (RVFV) infection in transgenic IFNAR(-\/-) mice induced by different DNA vaccination regimens. Vaccine 28, 2937\u20132944 (2010).","journal-title":"Vaccine"},{"key":"1200_CR31","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.virol.2006.09.035","volume":"359","author":"SR Gerrard","year":"2007","unstructured":"Gerrard, S. R., Bird, B. H., Albarino, C. G. & Nichol, S. T. The NSm proteins of Rift Valley fever virus are dispensable for maturation, replication and infection. Virology 359, 459\u2013465 (2007).","journal-title":"Virology"},{"key":"1200_CR32","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","volume":"27","author":"LJMH Reed","year":"1938","unstructured":"Reed, L. J. M. H. A simple method of estimating fifty per cent endpoints. Am. J. Epidemiol. 27, 493\u2013497 (1938).","journal-title":"Am. J. Epidemiol."},{"key":"1200_CR33","doi-asserted-by":"crossref","unstructured":"Xu, L. et al. A cross-sectional study of SARS-CoV-2 seroprevalence between Fall 2020 and February 2021 in Allegheny County, Western Pennsylvania, USA. Pathogens 10, 710 (2021).","DOI":"10.3390\/pathogens10060710"},{"key":"1200_CR34","doi-asserted-by":"crossref","unstructured":"Barbeau, D. J. et al. Rift Valley fever virus infection causes acute encephalitis in the ferret. mSphere 5, e00798-20 (2020).","DOI":"10.1128\/mSphere.00798-20"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01200-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01200-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01200-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T07:13:13Z","timestamp":1751440393000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01200-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1200"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01200-2","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"23 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.H.B. is an inventor of patents describing the development of the \u0394NSs-\u0394NSm-rZH501 vaccine candidate technology (USPTO: 8,673,629, 9,439,935, and 10,064,933). The remaining authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"141"}}